Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated, HR-positive, HER2-negative invasive breast cancer: A systematic review
Journal of Oncology Pharmacy Practice
Published online on June 17, 2025
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
The treatment paradigm for advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer has advanced rapidly over the last decade. The discovery of mutations in thePIK3CAgene and ...
The treatment paradigm for advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer has advanced rapidly over the last decade. The discovery of mutations in thePIK3CAgene and ...